Benefiting from the most efficient or adapted therapy to cure from disease and/or to be cured with the best quality of life during treatment


Providing innovative and non-invasive Blood-based In Vitro Diagnostic to predict patient response to a certain therapy


Making a diagnosis, treating, providing medical follow-up with the objective to personalize patient’s medical care in taking into account individual differences

GemciTest ®

The first diagnostic to predict the patient response in pancreatic cancer treatment


A rare and “silent” disease with no symptom early on, difficult to diagnose and cure.


A blood-based molecular test (RUO diagnostic) to predict patient’s therapeutic response


The less toxic and expensive chemotherapy in pancreatic cancer treatment


A combination of biomarkers to identify patients most likely to benefit from gemcitabine

Prescribing the right treatment to the right patient requires funds.
To obtain more information about ACOBIOM’s developments, please visit the “Investors” page

Our Expertises

Acobiom is an innovative biotechnology company specialized in the discovery of new biomarkers and in the development of innovative diagnostics.


Analyses of biological phenotypes; investigation of gene expression changes; Identification & validation of acid nucleic (DNA, RNA, miRNA, small RNA, coding & non coding RNA) biomarkers based on Sequencing/NGS & PCR technologies.


Treatments & analyses of sequencing/omics big data through a proprietary suite of Bioinformatic and Biostatistic tools; Development of a 21,000 Human RNA-Seq database, in-silico investigations through public & proprietary databases.


Biomarkers and diagnostics “to optimize a specific preventive, diagnostic or therapeutic intervention in a given subpopulation of patients, which would most likely to benefit from it”.


A unique scientific and technical expertise associated with 20-year experience in genomics & transcriptomics, in sequencing/NGS & PCR technologies, in performing RNA-Seq / ChIP-seq analyses, and PCR / qPCR / qRT-PCR experiences.

Latest News

Acobiom uses real world data (RWD).

Real-World Data as the basis for predictive diagnostics developed by ACOBIOM

Based on Real-World Data and Real-World Evidence, ACOBIOM contributes to better therapeutic decisions and thus allows to give the right treatment to the right patient.

Read more
ACOBIOM propose un nouveau service: mesurer l’inflammation dans les organes et le sang par Digital PCR ou PCR en Temps-Réel

ACOBIOM provides a new service: measuring inflammation in organs and blood by Digital or Real-Time PCR

Based on its proprietary database of gene expression profiles and its scientific expertise, ACOBIOM selected a panel of genes to measure inflammation in organs and blood. This Digital or Real-Time PCR assay allows the company to extend its range of services.

Read more
Real Time qPCR plaque

Target genes and specific reference genes, a unique marriage for successful RT-PCR experiments

Gene expression analyses by real-time PCR (or qPCR) are currently used to measure drug effects or to identify subpopulations of patients mostly likely to benefit from a specific therapy. The success of a qPCR experiment relies on the combination of a unique triptych: the selection of relevant and regulated target genes, the identification of a couple or more stable and experiment-specific reference genes, also called housekeeping genes, and robust statistical analyses. Thus, if some consider the target genes as the Kings of their experiment, the reference genes are the Queens of the equation!

Read more

Since its foundation, Acobiom has always been at the forefront of Medical Innovation.

Acobiom was founded by Didier Ritter and Dr David Piquemal under the name « Skuldtech » to promote the gene expression profile (transcriptome) approach with the objective to discover RNA biomarkers, to develop diagnostics, and to improve the patient’s medical care.

Big Data - Acobiom

Contact us